In consideration of the reduced compliance of peptide GLP-1 receptor agonists due to subcutaneous injection, oral micromolecular GLP-1 receptor agonists such as orforglipron have already in clinical trials, which can reduce body weight and improve cardiac metabolism in adults with obesity (Wharton et al 2023) (Fig
Battistin L, Pizzolato G, Dam M, and et al
SURMOUNT-5: Tirzepatide vs Semaglutide for Weight Management
What is fibermaxxing?: how a high-fiber diet can help prevent cancer
For instance, two 3,000mAh 20C packs in parallel become 6,000mAh 20C, which can now handle 120A continuous
Ozempic is considered a first-line treatment for Type 2 diabetes only if you have cardiovascular disease (CV disease) or are at high risk for CV disease